Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

Abstract

To grow and metastasize, solid tumours must develop their own blood supply by neo-angiogenesis. Thalidomide inhibits the processing of mRNA encoding peptide molecules including tumour necrosis factor-alpha (TNF-alpha) and the angiogenic factor vascular endothelial growth factor (VEGF). This study investigated the use of continuous low dose Thalidomide in patients with a variety of advanced malignancies. Sixty-six patients (37 women and 29 men; median age, 48 years; range 33-62 years) with advanced measurable cancer (19 ovarian, 18 renal, 17 melanoma, 12 breast cancer) received Thalidomide 100 mg orally every night until disease progression or unacceptable toxicity was encountered. Three of 18 patients with renal cancer showed partial responses and a further three patients experienced stabilization of their disease for up to 6 months. Although no objective responses were seen in the other tumour types, there were significant improvements in patients' sleeping (P < 0.05) and maintained appetite (P < 0.05). Serum and urine concentrations of basic fibroblast growth factor (bFGF), TNF-alpha and VEGF were measured during treatment and higher levels were associated with progressive disease. Thalidomide was well tolerated: Two patients developed WHO Grade 2 peripheral neuropathy and eight patients developed WHO grade 2 lethargy. No patients developed WHO grade 3 or 4 toxicity. Further studies evaluating the use of Thalidomide at higher doses as a single agent for advanced renal cancer and in combination with biochemotherapy regimens are warranted.

References 35

1. 1.

   Asscher W. Safety of thalidomide. BMJ. 1994;309(6948):193-194.

   Not in our library10.1136/bmj.309.6948.193c

2. 2.

   Battegay E. J. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med (Berl). 1995;73(7):333-346.

   Not in our library10.1007/bf00192885

3. 3.

   Burrows F. J., Thorpe P. E. Vascular targeting--a new approach to the therapy of solid tumors. Pharmacol Ther. 1994;64(1):155-174.

   Not in our library10.1016/0163-7258(94)90037-x

4. 4.

   Bussolino F., Albini A., Camussi G., Presta M., Viglietto G., Ziche M., Persico G. Role of soluble mediators in angiogenesis. Eur J Cancer. 1996;32A(14):2401-2412.

   Not in our library10.1016/s0959-8049(96)00390-5

5. 5.

   Ching L. M., Xu Z. F., Gummer B. H., Palmer B. D., Joseph W. R., Baguley B. C. Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer. 1995;72(2):339-343.

   Not in our library10.1038/bjc.1995.335

6. 6.

   Crawford C. L. Use of thalidomide in leprosy. Adverse Drug React Toxicol Rev. 1994;13(4):177-192.

   Not in our library

7. 7.

   D'Amato R. J., Loughnan M. S., Flynn E., Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91(9):4082-4085.

   Not in our library10.1073/pnas.91.9.4082

8. 8.

   Eisenbud L., Horowitz I., Kay B. Recurrent aphthous stomatitis of the Behçet's type: successful treatment with thalidomide. Oral Surg Oral Med Oral Pathol. 1987;64(3):289-292.

   Not in our library10.1016/0030-4220(87)90006-5

9. 9.

   Erhard H., Rietveld F. J., van Altena M. C., Bröcker E. B., Ruiter D. J., de Waal R. M. Transition of horizontal to vertical growth phase melanoma is accompanied by induction of vascular endothelial growth factor expression and angiogenesis. Melanoma Res. 1997;7(Suppl 2):S19-S26.

   Not in our library

10. 10.

    FULLERTON P. M., KREMER M. Neuropathy after intake of thalidomide (distaval). Br Med J. 1961;2(5256):855-858.

    Not in our library10.1136/bmj.2.5256.855

11. 11.

    Fajardo L. F., Kwan H. H., Kowalski J., Prionas S. D., Allison A. C. Dual role of tumor necrosis factor-alpha in angiogenesis. Am J Pathol. 1992;140(3):539-544.

    Not in our library

12. 12.

    Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1(1):27-31.

    Not in our library10.1038/nm0195-27

13. 13.

    Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med. 1995;333(26):1757-1763.

    Not in our library10.1056/nejm199512283332608

14. 14.

    Gasparini G. Clinical significance of the determination of angiogenesis in human breast cancer: update of the biological background and overview of the Vicenza studies. Eur J Cancer. 1996;32A(14):2485-2493.

    Not in our library10.1016/s0959-8049(96)00376-0

15. 15.

    Hamada J., Cavanaugh P. G., Lotan O., Nicolson G. L. Separable growth and migration factors for large-cell lymphoma cells secreted by microvascular endothelial cells derived from target organs for metastasis. Br J Cancer. 1992;66(2):349-354.

    Not in our library10.1038/bjc.1992.269

16. 16.

    Haslett P. A. Anticytokine approaches to the treatment of anorexia and cachexia. Semin Oncol. 1998;25(2 Suppl 6):53-57.

    Not in our library

17. 17.

    Ingber D., Fujita T., Kishimoto S., Sudo K., Kanamaru T., Brem H., Folkman J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature. 1990;348(6301):555-557.

    Not in our library10.1038/348555a0

18. 18.

    Jacobson J. M., Greenspan J. S., Spritzler J., Ketter N., Fahey J. L., Jackson J. B., Fox L., Chernoff M., Wu A. W., MacPhail L. A. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med. 1997;336(21):1487-1493.

    Not in our library10.1056/nejm199705223362103

19. 19.

    Koo A. S., Armstrong C., Bochner B., Shimabukuro T., Tso C. L., deKernion J. B., Belldegrum A. Interleukin-6 and renal cell cancer: production, regulation, and growth effects. Cancer Immunol Immunother. 1992;35(2):97-105.

    Not in our library10.1007/bf01741856

20. 20.

    Lopez Hänninen E., Kirchner H., Atzpodien J. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol. 1996;155(1):19-25.

    Not in our library

21. 21.

    Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981;47(1):207-214.

    Not in our library10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6

22. 22.

    Mizutani Y., Bonavida B., Nio Y., Yoshida O. Overcoming TNF-alpha and drug resistance of human renal cell carcinoma cells by treatment with pentoxifylline in combination with TNF-alpha or drugs: the role of TNF-alpha mRNA downregulation in tumor cell sensitization. J Urol. 1994;151(6):1697-1702.

    Not in our library10.1016/s0022-5347(17)35347-8

23. 23.

    Parman T., Wiley M. J., Wells P. G. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med. 1999;5(5):582-585.

    Not in our library10.1038/8466

24. 24.

    Powell R. J., Gardner-Medwin J. M. Guideline for the clinical use and dispensing of thalidomide. Postgrad Med J. 1994;70(830):901-904.

    Not in our library10.1136/pgmj.70.830.901

25. 25.

    Schiffenbauer Y. S., Abramovitch R., Meir G., Nevo N., Holzinger M., Itin A., Keshet E., Neeman M. Loss of ovarian function promotes angiogenesis in human ovarian carcinoma. Proc Natl Acad Sci U S A. 1997;94(24):13203-13208.

    Not in our library10.1073/pnas.94.24.13203

26. 26.

    Talbot D. C., Brown P. D. Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur J Cancer. 1996;32A(14):2528-2533.

    Not in our library10.1016/s0959-8049(96)00398-x

27. 27.

    Tramontana J. M., Utaipat U., Molloy A., Akarasewi P., Burroughs M., Makonkawkeyoon S., Johnson B., Klausner J. D., Rom W., Kaplan G. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med. 1995;1(4):384-397.

    Not in our library

28. 28.

    Voest E. E., Kenyon B. M., O'Reilly M. S., Truitt G., D'Amato R. J., Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst. 1995;87(8):581-586.

    Not in our library10.1093/jnci/87.8.581

29. 29.

    Vogelsang G. B., Farmer E. R., Hess A. D., Altamonte V., Beschorner W. E., Jabs D. A., Corio R. L., Levin L. S., Colvin O. M., Wingard J. R. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med. 1992;326(16):1055-1058.

    Not in our library10.1056/nejm199204163261604

30. 30.

    Weidmann E., Bergmann L., Stock J., Kirsten R., Mitrou P. S. Rapid cytokine release in cancer patients treated with interleukin-2. J Immunother (1991). 1992;12(2):123-131.

    Not in our library10.1097/00002371-199208000-00007

31. 31.

    Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol. 1995;147(1):9-19.

    Not in our library

32. 32.

    Weidner N., Semple J. P., Welch W. R., Folkman J. Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med. 1991;324(1):1-8.

    Not in our library10.1056/nejm199101033240101

33. 33.

    Wettstein A. R., Meagher A. P. Thalidomide in Crohn's disease. Lancet. 1997;350(9089):1445-1446.

    Not in our library10.1016/s0140-6736(05)64206-7

34. 34.

    Yoneda T., Alsina M. A., Chavez J. B., Bonewald L., Nishimura R., Mundy G. R. Evidence that tumor necrosis factor plays a pathogenetic role in the paraneoplastic syndromes of cachexia, hypercalcemia, and leukocytosis in a human tumor in nude mice. J Clin Invest. 1991;87(3):977-985.

    Not in our library10.1172/jci115106

35. 35.

    Ziegler J. Angiogenesis research enjoys growth spurt in the 1990s. J Natl Cancer Inst. 1996;88(12):786-788.

    Not in our library10.1093/jnci/88.12.786

Cited by papers we hold 1

• Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer · 2007
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.